Download full text PDF

Makiev G.G. Student, North Ossetian State Medical Academy (Vladikavkaz) Gurina A.E. Ph.D. (Med.), Associate Professor, North Ossetian State Medical Academy (Vladikavkaz) Gabolaeva N.A. Assistant, North Ossetian State Medical Academy (Vladikavkaz) E-mail:

A study was conducted for the influence of mexidol on the condition of pro- and antioxidant systems in rats with an experimental acute respiratory distress syndrome (ARDS). The processes of lipid peroxidation (LPO) by malondialdehyde (MDA) and hydroperoxides content, change in enzyme activity of the antioxidant protection (AOP): catalase, superoxide dismutase (SOD) and degree of disease development were assessed in the experiment. The ARDS model was created by an intraperitoneal injection of 0.1% adrenaline solution at a dose of 15 mg/kg. The rats were divided into 4 groups: I-control; II- with experimental ARDS; III and IV - with intraperitoneal injection of mexidol at a dose of 200 and 400 mg/kg, respectively, and fur-ther modeling of the ARDS. The pulmonary edema was identified visually and by the morpho-histological characterization. During the experiment it was proved that LPO processes and AOP are activated in this pathology. There has been a decrease of the MDA content by 29,43%, hydroperoxides content by 58,55%, catalase activity lower by a factor of 1,17 with a dose of 400 mg/kg. However, the value of catalase activity remains higher than in the control group. This indicates a reduction in the toxic effect of reactive oxygen species (ROS). There has been an increase in the activity of SOD by a factor of 1,05 regarding II, which is one of the effects of mexidol. The results after correction by drug in a dose of 200 mg/kg are similar, but less pronounced. In addition it was detected that mexidol affects the lifetime: it increased by 26% in III and by 65.5% in IV. Thus, mexidol under the experimental ARDS has a powerful antihypoxic and antioxidant effect contributing to reducing the damaging effects of ROS and LPO intensity. This leads to a significant extension of the lifetime. There is no this effect in other drugs used for this syndrome.

acute respiratory distress syndrome
antioxidant protection
lipid peroxidation

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

  1. Ranieri V.M., Rubenfeld G.D., Thompson B.T., Ferguson N.D. Acute respiratory distress syndrome: the Berlin Definition // Journal of the American Medical Association, Am. Med. Ass. 2012. R. 23-307.
  2. Fanelli V., Ranieri, V.M. Mechanisms and clinical consequences of acute lung injury // Ann. Am. Thorac. Soc. 2015. № 12. R. 1-8.
  3. Kassil' V.L., Sapicheva Ju.Ju. Ostryj respiratornyj distress-sindrom igipoksemija. M.: MEDpress-inform. 2016. S. 9.
  4. Kassil' V.L. Ostryj vnelegochnyj respiratornyj distress-sindrom: opredelenie, etiopatogenez, klinicheskie i laboratornye projavlenija // Klinicheskaja onkogematologija. 2011. № 4. R. 1-54.
  5. Gritsaj A.I., Jaroshetskij A.I. Diagnostika i intensivnaja terapija ostrogo respiratornogo listress-sindroma. M., 2015. S. 38.
  6. Kulikov O.A., Hasan I.A. M., Ageev V.P., Dolgacheva I.S., Marochkina E.E. Vlijanie etilmetilgidroksipiridina suktsinata na funktsiju legkih pri eksperimental'nom ostrom respiratornom distress-sindrome // Zdorov'e i obrazovanie v XXI veke. 2016. № 18. S. 2-580.
  7. Danilova L.A. Spravochnik po laboratornym metodam issledovanija. SPb: Piter. 2003. 733 s.
  8. Kamyshnikov V.S. Kliniko-biohimicheskaja laboratornaja diagnostika. Minsk: Interpresservis. 2003. S. 463-2.